Valion Bio shares are trading lower. The company announced a clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center.

Valion Bio Appoints Lisa Wolf To Expanded Roles Of President, COO, Effective Immediately

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company, today announced strategic changes to its management team and Board of Directors designed to

8-K filing — Valion Bio, Inc. (VBIO)

Filed: 2026-09-01 AccNo: 0001683168-26-006848 Size: 271 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Valion Bio shares are trading lower after the company announced a 1-for-25 reverse stock split.

Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31

Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of